Precision medicine for diagnosis of pancreatic and biliary tract neoplasm using cell-free nucleic acid and residual specimens

A minimally invasive test for diagnosis of pancreatic and biliary tract neoplasm using cell-free nucleic acid and residual specimens - A minimally invasive test for diagnosis of pancreatic and biliary tract neoplasm

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047326

Enrollment

650

Registered

2022-04-01

Start date

2022-01-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pancreatic and biliary tract neoplasm and their precancerous lesions, and individuals at high risk of developing pancreatic and biliary tract cancers, and patients with benign gastrointestinal disorders including cholelithiasis and gastroduodenal ulcer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?Patients with pancreatic and biliary tract neoplasm including benign/pre-cancerous lesions, individuals at high risk of developing these tumors diagnosed at Asahikawa Medical University Hospital and affiliated/ collaborating hospitals. ?Patients aged 20 years or older at the time of diagnosis, regardless of gender ?Patients with a benign digestive disorder such as gall stone and gastroduodenal ulcer. ?Patients with written informed consent.

Exclusion criteria

Exclusion criteria: ?Patients with severe heart disease ?Patients with severe renal disease ?Patients with serious mental illness ?Patients complicated with severe infection ?Patients with severe diabetes ?Patients with severe dehydration and malnutrition ?Patients who have other serious complications and are considered difficult to participate ?Patient who judged inappropriate by an attendant physician

Design outcomes

Primary

Measure	Time frame
Diagnostic value of quantitative detection and monitoring of tumor-associated alterations in body fluid cell-free nucleic acid and tissue-derived nucleic acid in pancreatic and biliary tract neoplasm.	—

Secondary

Measure	Time frame
Surveillance of individuals at high risk of developing pancreatic and biliary tract neoplasm by quantitative detection and monitoring of tumor-associated alterations in cell-free nucleic acid and tissue-derived nucleic acid.	—

Countries

Japan

Contacts

Public ContactYusuke Mizukami

Asahikawa Medical University Division of Gastroenterology, Department of Medicine

mizu@asahikawa-med.ac.jp0166-68-2462

Outcome results